Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106428 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT03106428 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 67 participants.
The verdict
NCT03106428, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected hematological malignancies who have relapsed after, or are refractory to prior standard therapy, and for whom there is no standard salvage regimen available.
Interventions
- DRUG MEDI7247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2020-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03106428
The ClinicalTrials.gov registry entry for NCT03106428 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI7247 is the first listed.
NCT03106428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03106428 about?
NCT03106428 is a clinical study titled "A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies". To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with sel...
What is the current status of trial NCT03106428?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2017-03-29. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT03106428?
The interventions under investigation include: MEDI7247 (DRUG).
Who is sponsoring clinical trial NCT03106428?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.